NextCure, Inc. (NASDAQ:NXTC) Given Average Rating of “Hold” by Analysts

NextCure, Inc. (NASDAQ:NXTC) has earned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $23.00.

NXTC has been the subject of several analyst reports. Zacks Research cut shares of NextCure from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a report on Monday, April 27th.

Hedge Funds Weigh In On NextCure

Several hedge funds have recently bought and sold shares of the company. Cable Car Capital LP boosted its holdings in shares of NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in shares of NextCure by 28.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after buying an additional 55,412 shares during the last quarter. Ikarian Capital LLC bought a new stake in shares of NextCure during the 4th quarter worth $3,382,000. Squadron Capital Management LLC bought a new stake in shares of NextCure during the 4th quarter worth $3,363,000. Finally, Exome Asset Management LLC bought a new stake in shares of NextCure during the 4th quarter worth $2,341,000. 42.65% of the stock is owned by institutional investors.

NextCure Stock Down 45.5%

Shares of NextCure stock opened at $3.38 on Tuesday. NextCure has a twelve month low of $2.83 and a twelve month high of $15.74. The company has a 50-day simple moving average of $9.91 and a two-hundred day simple moving average of $11.45. The stock has a market capitalization of $12.20 million, a price-to-earnings ratio of -0.20 and a beta of 1.31.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, sell-side analysts anticipate that NextCure will post -7.91 earnings per share for the current fiscal year.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.